Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017 Read more about Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Read more about Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March Read more about Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting Read more about Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback Read more about Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference Read more about Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts Read more about Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy Read more about Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science Read more about Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy Read more about Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy
